What To Know
- Currently, Jack is the chairman and CEO of HeMo Bioengineering Limited, a medical device company established in 2017, primarily focusing on neurovascular intervention in Asia, with its current manufacturing and marketing and sales headquarters in China.
- Previously, Jack was the CEO of Biosensors International, a pioneer in interventional cardiology devices, where he was responsible for the company’s significant growth and strategic direction leading to the acquisition of several successful companies.
Jack Wang, Ph.D. has been appointed to the Board of Directors of Pressao Medical. Wang is an accomplished business leader with more than 20 years’ experience in the medical device industry (including Biosensors International, Johnson & Johnson and Guidant Corporation) with a successful track record in business execution and exits.
Currently, Jack is the chairman and CEO of HeMo Bioengineering Limited, a medical device company established in 2017, primarily focusing on neurovascular intervention in Asia, with its current manufacturing and marketing and sales headquarters in China. Previously, Jack was the CEO of Biosensors International, a pioneer in interventional cardiology devices, where he was responsible for the company’s significant growth and strategic direction leading to the acquisition of several successful companies.
A graduate of Case Western Reserve University, Jack has been granted more than 20 U.S. and European patents in medical devices and technology and has published more than 30 scientific papers on polymer materials and processing.
“We are excited to welcome Dr. Jack Wang to our board. His unique combination of vast industry experience and perspective will be critical as we prepare for international market entry,” says Shawn Moaddeb, the chairman of Pressao Medical.
